Aligned with the contractual duration of PCP Phase II and the Monitoring Team calendar as referred to in phase IV.B.3 “PCP Phase III (Monitoring): Final prototype development including adaptations and integrations and further pre-clinical validation and preliminary economic impact evaluation (if applicable)”. Usually between 6 to 18 months.
To develop a fully functional prototype that integrates all technical improvements, adaptations, and interoperability requirements from previous phases. This includes tailoring the solution to different procurer needs, workflows, and IT environments, while ensuring regulatory compliance and user acceptability.
✅ Integrate feedback systematically: Incorporate all technical, clinical, and user insights from previous phases to ensure the final prototype is robust, interoperable, and aligned with each procurer’s context.
✅ Concentrate on understanding the different organisations involved in the pilots and get the most in terms of usability, acceptability, flexibility, and what makes a difference for the people involved.
✅ Validate comprehensively: Conduct structured preclinical validation covering usability, safety, interoperability, and performance, supported by traceable documentation and standardized protocols.
❌ Avoid Incomplete integration or adaptation, neglecting site-specific workflows or IT environments leads to deployment and compatibility issues.
❌ Overlooking economic impact and compliance considerations, such as omitting essential regulatory documentation, can significantly undermine credibility and limit the likelihood of adoption..
❌ Avoid expectative too ambitious with respect to what can be obtained from the pilot and not getting the right measurement from the opportunity.
Browse our directory of experts who can provide professional guidance.
